Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $328 | In Stock | |
5 mg | $859 | In Stock | |
10 mg | $1,270 | In Stock | |
25 mg | $1,890 | In Stock | |
50 mg | $2,550 | In Stock |
Description | Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis. |
In vitro | METHODS: Ozoralizumab (ATN-103) (0.1-1000pM) was used to treat L929 cells and its high TNFα neutralizing potency was determined. RESULTS: Ozoralizumab (ATN-103) has high TNFα neutralizing potency, with very similar binding and dissociation properties, and KD values for human TNFα and monkey TNFα are 20.2 pM and 16.1 pM, respectively. [1] |
In vivo | METHODS: Tg197 mice were injected subcutaneously with 1 mg/kg dose of Ozoralizumab (ATN-103) twice weekly to evaluate the formation of ADA against each anti-TNFα antibody and the effect of long-term administration of these anti-TNFα antibodies on TNFα-mediated TNFα in Tg197 mice. Efficacy of polyarthritis. RESULTS: Ozoralizumab (ATN-103) significantly and comparably reduced arthritis scores. [1] |
Alias | TS-152, ATN-103 |
Molecular Weight | 38.44 kDa |
Cas No. | 1167985-17-2 |
Storage | store at low temperature | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.